Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Novel mechanism of FNAIT: effect of maternal anti-aIIb antibodies on hematopoietic stem cells.

FY 2022-23

Summary
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is serious bleeding disorder affecting 0.5-1.5/1000 newborn neonate. It is caused by maternal immmune responses to fetal, paternally-derived polymorphisms on certain platelet glycoproteins. Anti-ß3 mediated FNAIT is by far the most commonly reported target in human cases of FNAIT, however, alphaIIb pairs exclusively with ß3 on platelets and has a similar number of polymorphisms, leaving the question of what differs between these two distinct FNAIT pathologies. Preliminary data by the first-of-its kind FNAIT animal models by our lab found that anti-alphaIIb FNAIT is more severe and causes significantly more frequent miscarriage compared to anti-ß3 FNAIT, suggesting its lower reported incidence may be due to difficulties in reporting cases of miscarriage. It is known that in both cases, anti-alphaIIb or ß3 antibodies induce platelet clearance, but alphaIIb is also expressed on HSCs throughout fetal development. Recent evidence suggests that alphaIIb plays a functional role in HSC migration and survival. Preliminary data from our mouse models demonstrate significant pancytopenia which may explain reduced placenta and liver size, as well as intrauterine growth restriction (IUGR). Whether pathogenic antibodies in FNAIT can cause apoptosis of HSCs, impair their function, or dysregulate their migration throughout fetal development is yet to be studied. This study will employ the use flow cytometry, immunofluorescence imaging, and various stem cell growth and migration assays to elucidate the effect of pathogenic alphaIIb antibodies on HSCs. We expect this study will elucidate a novel mechanism of miscarriage in FNAIT pathology and improve our overall understanding of fetal hematopoietic development.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
488150
Name
Khoury Christopher J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel mechanism of FNAIT: effect of maternal anti-aIIb antibodies on hematopoietic stem cells.
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Allo-Immune Response; Alphaiib; Fetal Development; Fetal Liver; Hematopoeisis; Hematopoietic Stem Cells; Miscarriage; Placenta; Platelets; Thrombocytopenia
Abstract
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is serious bleeding disorder affecting 0.5-1.5/1000 newborn neonate. It is caused by maternal immmune responses to fetal, paternally-derived polymorphisms on certain platelet glycoproteins. Anti-ß3 mediated FNAIT is by far the most commonly reported target in human cases of FNAIT, however, alphaIIb pairs exclusively with ß3 on platelets and has a similar number of polymorphisms, leaving the question of what differs between these two distinct FNAIT pathologies. Preliminary data by the first-of-its kind FNAIT animal models by our lab found that anti-alphaIIb FNAIT is more severe and causes significantly more frequent miscarriage compared to anti-ß3 FNAIT, suggesting its lower reported incidence may be due to difficulties in reporting cases of miscarriage. It is known that in both cases, anti-alphaIIb or ß3 antibodies induce platelet clearance, but alphaIIb is also expressed on HSCs throughout fetal development. Recent evidence suggests that alphaIIb plays a functional role in HSC migration and survival. Preliminary data from our mouse models demonstrate significant pancytopenia which may explain reduced placenta and liver size, as well as intrauterine growth restriction (IUGR). Whether pathogenic antibodies in FNAIT can cause apoptosis of HSCs, impair their function, or dysregulate their migration throughout fetal development is yet to be studied. This study will employ the use flow cytometry, immunofluorescence imaging, and various stem cell growth and migration assays to elucidate the effect of pathogenic alphaIIb antibodies on HSCs. We expect this study will elucidate a novel mechanism of miscarriage in FNAIT pathology and improve our overall understanding of fetal hematopoietic development.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Khoury, Christopher J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~